Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
Paul M. Scola(Bristol-Myers Squibb (United States)), Fiona McPhee(Bristol-Myers Squibb (United States)), Eric Hughes(The University of Texas at San Antonio Health Science Center), Barbara Zheng(Bristol-Myers Squibb (United States)), Anthony J. Cocuzza(Bristol-Myers Squibb (United States)), Jay O. Knipe(Bristol-Myers Squibb (United States)), Paul Falk(Bristol-Myers Squibb (United States)), Li‐Qiang Sun(Bristol-Myers Squibb (United States)), Stephen Adams(Bristol-Myers Squibb (Germany)), Jialong Zhu(Bristol-Myers Squibb (United States)), Paul Lévesque(Bristol-Myers Squibb (United States)), Donna M. Bilder(Bristol-Myers Squibb (United States)), Richard J. Colonno(Assembly Biosciences (United States)), Christoph Gesenberg(Bristol-Myers Squibb (Germany)), Tatyana Zvyaga(Bristol-Myers Squibb (Germany)), Nicholas A. Meanwell(Mario Negri Institute for Pharmacological Research), Herbert E. Klei(Bristol-Myers Squibb (United States)), Qi Gao(Merck & Co., Inc., Rahway, NJ, USA (United States)), Piyasena Hewawasam(Bristol-Myers Squibb (United States)), Stanley V. D’Andrea(Bristol-Myers Squibb (United States)), Guangzhi Zhai(Bristol-Myers Squibb (United States)), Diana Barry(Bristol-Myers Squibb (United States)), Danshi Li(Montreal Heart Institute), Alan Xiangdong Wang(Bristol-Myers Squibb (United States)), Ramkumar Rajamani(Bristol-Myers Squibb (United States)), Brian L. Venables(Bristol-Myers Squibb (United States)), Michael Sinz(Rutgers, The State University of New Jersey), Fei Yu(Yunnan Academy of Agricultural Sciences), Keith D. Combrink(Bristol-Myers Squibb (United States)), Dennis Hernandez(Bristol-Myers Squibb (United States)), Min S. Lee(University of California, Los Angeles), Amy K. Sheaffer(Bristol-Myers Squibb (United States)), Jie Chen(Bristol-Myers Squibb (United States)), Yan Chen(Zhengzhou University), Jianqing Li(Nanjing University of Chinese Medicine), Wenying Li(Shanghai Jiao Tong University), Ny Sin(Bristol-Myers Squibb (United States)), Chaoqun Chen(Bristol-Myers Squibb (United States)), Yong Qiang Tu(Lanzhou University), Yong–Hae Han(Bristol-Myers Squibb (United States)), Andrew C. Good(Bristol-Myers Squibb (United States)), Jeffrey A. Campbell(Bristol-Myers Squibb (United States)), Dennis M. Grasela(Bristol-Myers Squibb (United States)), Susan Jenkins(Bristol-Myers Squibb (Germany)), Kenneth S. Santone(Bristol-Myers Squibb (Germany)), Caly Chien(Bristol-Myers Squibb (Germany)), Jan Willem Thuring(Bristol-Myers Squibb (United States)), Sing‐Yuen Sit(Bristol-Myers Squibb (United States)), Min Ding(Jiangsu University)
Cited by 69
Related Papers
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
|Nature|2010|940
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #
|Hepatology|2009|815
All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study
|Hepatology|2015|689
CYP3A4 Induction by Drugs: Correlation between a Pregnane X Receptor Reporter Gene Assay and CYP3A4 Expression in Human Hepatocytes
|Drug Metabolism and Disposition|2002|447
Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
|Nature Communications|2020|432